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Introduction
Respiratory tract infections are globally responsible for one-third of infectious disease–associ-
ated mortality, accounting for 4.3 million annual deaths. Among these, fungal infections of the
respiratory tract are largely unrecognized, and the true burden is elusive [1]. Despite treatment,
most invasive fungal infections are associated with high mortality rates of>50% [2]. In general,
fungal infections of the respiratory tract are considered synonymous with invasive pulmonary
infections caused by Aspergillus spp. and in some centers by Mucorales. However, over the last
decade, a number of uncommon filamentous fungi, such as Scedosporium, Fusarium, Penicil-
lium, melanized moulds, and basidiomycetes, have emerged as etiological agents of well-char-
acterized respiratory disorders. It is therefore that the term “respiratory mycosis” has now
broadened to include not just invasive disease but also lesser-recognized entities such as fungal
ball, severe asthma with fungal sensitization (SAFS), fungus-associated chronic cough (FACC),
allergic bronchopulmonary mycosis (ABPM), and allergic fungal rhinosinusitis (AFRS) [3–6].
Notably, both FACC and SAFS have recently been recognized as distinct clinical entities [7,8].
The former manifests as chronic intractable cough in response to pharyngeal colonization by
filamentous basidiomycetes, which has been associated with allergic sensitization [7]. The lat-
ter, on the other hand, is a reference to poorly controlled asthma, despite optimal management,
with evidence of fungal sensitization (short of being labelled ABPM) [6]. Aspergillus spp. are
considered to be the major culprit of SAFS, although a range of other fungi, such as Alternaria
and Cladosporium spp., are also involved [8]. Both conditions respond favourably to oral anti-
fungal agents, thereby proving a definite role of fungi [9,10]. Moreover, new pathophysiological
associations hitherto unknown, such as fungal sensitization and ABPM in patients with
chronic obstructive pulmonary disease (COPD), are unfolding [11,12]. Further, emergence of
resistance in filamentous fungi to azole antifungal drugs used as mainstay of therapy is another
challenging scenario witnessed in the last two decades. This emerging problem is primarily
attributed to the widespread usage of azole fungicides in the environment for agricultural and
material preservation practices [13]. Here, we aim to provide an overview of the ever-expand-
ing spectrum of human respiratory mycoses and the fungi involved, excluding Aspergillus and
Mucorales.
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Filamentous Ascomycetes in Respiratory Tract Infections
Several soil-inhabiting genera of the ascomycete order Onygenales, such asHistoplasma, Cocci-
dioides, Blastomyces, and Penicillium (Talaromyces)marnefeii, are thermally dimorphic patho-
gens, primarily inflicting lungs, while other ascomycetes are at best considered as opportunistic
pathogens on a background of underlying local and/or systemic risk factors. The latter group
includes most fungi encountered frequently in clinical practice. With the exception of asper-
gilli, which are the commonest respiratory fungal pathogens, other filamentous fungi causing
respiratory diseases include Mucorales, black fungi, and species of Fusarium, Scedosporium,
and Penicillium. Fusarium spp., conventionally regarded as agents of onychomycosis, are now
well known to cause fatal respiratory mycosis. Pulmonary infections are most commonly seen
with the Fusarium solani species complex, which mimics aspergillosis and is associated with a
worse outcome given the resistance to common antifungal agents [14], while F. vasinfectum is
associated with ABPM and hypersensitivity pneumonitis [15,16]. Similarly, species of Scedos-
porium apiospermum complex and Lomentospora prolificans (previously Scedosporium prolifi-
cans) are considered “emerging” human pathogens. Clinically, all organ systems can be
infected, although pulmonary infections are the most common [17]. L. prolificans typically
causes infections in immunocompromised patients, which are associated with high mortality.
The spectrum of respiratory diseases due to S. apiospermum ranges from sinusitis, pulmonary
fungal ball, ABPM, and pneumonia [17]. Scedosporium bears a curious association with cystic
fibrosis, in which it is seen as a frequently isolated filamentous mould, second only to Aspergil-
lus [17]. S. aurantiacum (a member of the S. apiospermum complex) is mainly isolated from
patients with cystic fibrosis and other chronic lung diseases. Treatment outcomes with Scedos-
porium spp. are usually poor, with L. prolificans being resistant to almost all antifungal agents
[17].
Also, species of Penicillium are emerging over the last few decades as opportunistic lung
pathogens. Among these, Talaromyces marnefeii is the fourth most common opportunistic
pathogen in HIV/AIDS in Southeast Asia. However, other species of Penicillium responsible
for respiratory infections include P. chrysogenum, P. citrinum, P. decumbens, P. piceum, P. com-
mune, and P. purpurogenum. Recently, P. oxalicum is recognized as a pulmonary pathogen in
patients with chronic respiratory diseases receiving long-term voriconazole therapy [18]. Inter-
estingly, this species exhibits reduced susceptibility to azoles and resulted in breakthrough
infections during voriconazole therapy. Also, other Penicillium spp. have high minimum inhib-
itory concentrations of voriconazole [19]. Lately, the epidemiology of invasive pulmonary
aspergillosis is also changing, and Aspergillus terreus has emerged as the third most important
Aspergillus species responsible for invasive aspergillosis in some centres in the United States
and Europe. Notably, A. terreus demonstrates poor in vivo and in vitro response to amphoteri-
cin B and is associated with higher mortality than more conventional Aspergillus spp. [20].
Filamentous Basidiomycetes (FBM) as Agents of Invasive
Respiratory Disease
The FBM, colloquially called white moulds, have begun to gain importance lately, with sys-
temic studies demonstrating the pathogenic potential of this group of fungi as agents of respira-
tory and systemic diseases. FBM are usually sterile in culture and appear as cottony white
colonies that make routine laboratory identification difficult (Fig 1A). Occasionally, specific
characteristics such as spicules, hyphal pegs, clamp connections, arthroconidia, and/or chlamy-
doconidia may be seen, but they best serve to distinguish FBM fungi from other hyaline asco-
mycetes (Fig 1B) [3,4,21]. In the past, isolation of these moulds from clinical samples was
labelled as contamination; however, lately, several reports incriminating many genera of the
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phylum Basidiomycota as agents of human disease have been published [4,21]. Notably, FBM
such as Schizophyllum commune, Bjerkandera adusta, Hormographiella aspergillata, Ceriporia
lacerata, Perennniporia spp., Tyromyces fissilis, and Irpex lacteus are described as agents of
respiratory diseases [4,5,22–24]. Substantial numbers of white moulds isolated from clinical
samples continue to be unidentified, perhaps because of the unavailability of GenBank
sequence data for identification [4]. Among the FBM, S. commune (Fig 1) is probably the best
studied, and in a review of 71 infections with S. commune, 94% were respiratory cases (Fig 1C)
Fig 1. Culture characteristics of Schizophyllum commune and computed tomography image of a patient with allergic S. commune infection. (a)
Sabouraud’s dextrose agar petri plate showing white cottony growth of non-sporulating basidiomycete (Schizophylum commune) after 10 days of incubation
at 28°C. (b) Lactophenol cotton blue mount of slide culture on potato dextrose agar of S. commune showing clamp connections and spicules after 2 weeks of
incubation at 28°C (400x). (c) Plate showing basidiocarp (fruiting body) of S. commune after 4–5 weeks of incubation at 28°C with periodic exposure to light.
(d) High-resolution computed tomography of thorax of patient with allergic bronchopulmonary mycosis due to S. commune showing central bronchiectasis in
both the upper lobes.
doi:10.1371/journal.ppat.1005491.g001
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[22]. Another FBM, H. aspergillata, has been reported from Europe and North America as a
cause of invasive, predominantly pulmonary disease in patients with haematological malignan-
cies and haematopoietic stem cell recipients and is associated with a high case fatality [4,25].
Sporotrichum (Phanaerochaete) pruinosum is best known for causing chronic lung disease and
allergic sensitization in patients with chronic respiratory diseases [4,26]. Lately, a number of
newer FBM have been reported as human pathogens. Perenniporia spp. and Ceriporia lacerata
have been incriminated in intracavitary pulmonary fungal ball and fungal pneumonia [23,24].
The list of medically relevant FBMmoulds is therefore by no means exhaustive, and with grow-
ing awareness among microbiologists and pulmonologists, it will expand in the future.
Spectrum of Noninvasive Diseases Caused by FBM
FBM are better known as allergens than agents of invasive disease, and their noninvasive respi-
ratory manifestations include colonization, allergen sensitization, and allergic sinopulmonary
mycoses. Allergic phenomena involving the lower respiratory tract can manifest as bronchial
asthma in atopic individuals, which has been attributed to S. commune and Bjerkandera adusta
[27–28] or ABPM due to S. commune (Fig 1D) [22], while that of the upper respiratory tract
manifests as allergic fungal sinusitis [4,22]. Also, sensitization against S. commune has been
reported in patients with COPD, but the clinical implication of this needs to be established
[11]. Further, FACC is mainly reported from Japan [5]. The FBM B. adusta has been shown to
colonize the pharynx of susceptible individuals and produce a chronic uneasiness that pro-
duces the cough [11]. In FACC patients, FBM have been found in induced sputum cultures [5].
It is pertinent to emphasize here that FBM are slow growers and require prolonged incubation
of culture plates for up to 10 days. This is in strong contrast to other filamentous moulds such
as Mucorales and Aspergillus, which grow within 2 to 3 days of incubation. Thus, the detection
of FBM is hampered in microbiology laboratories that discard culture plates of respiratory
specimens within 2 days. Furthermore, it has been proposed that a subset of patients with
FACC exhibit sensitization to B. adusta, thereby displaying allergic fungal cough (AFC) that is
more severe and difficult to control than the nonsensitized patients with FACC [7]. Low-dose
itraconazole has been proposed as therapy for FACC, but the efficacy of this intervention is not
unequivocally proven yet [10]. Another unique bronchopulmonary colonization syndrome
attributable to S. commune has been reported exclusively from Japan and involves bronchial
impaction of mucus loaded with fungal hyphae [29].
Black Fungi in the Human Respiratory Tract
Most melanized fungi that cause infections are free-living plant saprobes implanted into human
tissue as a result of trauma, but respiratory mycoses occur secondary to inhalation of fungal
spores. The moulds implicated in respiratory infections belong to the orders Chaetothyriales
(Exophiala), Pleosporales (Alternaria, Bipolaris, Curvularia, and Exserohilum), Sordiales (Chae-
tomium), and Venturiales (Verruconis) of Ascomycota [30]. Among the Pleosporales, Alternaria
alternata and species of Bipolaris, Curvularia, and Exserohilum are associated with AFRS, bron-
chial asthma, hypersensitivity pneumonitis, ABPM, and invasive lung disease [15,31–34]. AFRS
is a form of polypoid chronic rhinosinusitis caused by type 1 hypersensitivity to fungal antigens.
In addition, the disease is characterized by elevated total serum immunoglobulin E, accumulation
of thick, eosinophil-laden mucin with noninvasive fungal hyphae within the paranasal sinuses,
and nasal polyposis. Although Aspergillus species are the most common cause of fungal sinus dis-
ease worldwide, allergic fungal rhinosinusitis is more commonly caused by black fungi [35].
Additionally, A. alternata is known to produce a severe form of asthma through outdoor allergen
sensitization [31]. Chaetomium spp. are rarely reported as agents of human disease, although
PLOS Pathogens | DOI:10.1371/journal.ppat.1005491 April 28, 2016 4 / 7
Chaetomium globosum has been characterized as a cause of fatal pneumonia in patients with hae-
matological malignancies or organ transplants [32,34]. Other respiratory infections attributable
to Chaetomium spp. include sinusitis and empyema [33]. Also, Verruconis gallopava andOchro-
conis spp. have been isolated from lower respiratory tract secretions and are responsible for inva-
sive and probably allergic lower respiratory tract disease [33,34].
Therapeutic Challenges and Future Perspectives
The majority of clinical experience with the above-mentioned diverse fungi represents isolated
cases or small series of infections. Therefore, evidence-based algorithms for specific treatment
are not available and therapy remains a challenge. Corticosteroids, administered systemically
or locally, remain the mainstay of treatment for allergic sinopulmonary manifestations. The
management of these disorders focuses on three facets. Firstly, as environmental modification
is usually impractical, the main focus is to suppress the inflammation with steroids. Alterna-
tively, systemic antifungal agents have been used successfully with the aim of reducing the fun-
gal load albeit best as adjuncts to steroids. Oral itraconazole has proven to be of benefit in
disorders such as FACC, SAFS, and ABPM [5,9,15]. Notably, FBM are resistant to echinocan-
dins, and the empirical use of these agents in patients had been associated with breakthrough
infections [25]. Also, polyene antifungals like amphotericin B show modest activity against
melanized fungi, though some species of Curvularia and Exophiala could be resistant [30].
To conclude, systematic studies examining the true burden, geographical distribution, and
underlying risk factors in patients with respiratory mycoses due to non-Aspergillus and mucor-
alean fungi remains unexplored. Clinical suspicion and broader recognition of FBM-associated
diseases among clinicians and microbiologists would improve therapeutic experience and, ulti-
mately, selection of better treatment strategies. It is pertinent to emphasize that thorough iden-
tification of non-sporulating moulds in clinical specimens is warranted in order to recognize
the clinical entities associated with FBM. Further, prima facie, there appears to be geographical
clustering of certain agents and their clinical associations, specifically in Asian countries, which
may either be attributable to the expertise and recognition of these agents from clinical samples
or other unknown factors that need to be determined. Lastly, to improve the outcome of the
diseases associated with these diverse fungi, more studies on pathogenicity, antifungal drug tri-
als, and standardized optimal treatment strategies are warranted.
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